Ying Du Sells 50,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $34.47, for a total value of $1,723,500.00. Following the completion of the transaction, the chief executive officer now owns 494,117 shares of the company’s stock, valued at approximately $17,032,212.99. The trade was a 9.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ying Du also recently made the following trade(s):

• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The stock was sold at an average price of $32.44, for a total value of $1,622,000.00.

Zai Lab Trading Up 5.6 %

Shares of ZLAB opened at $35.91 on Thursday. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $36.60. The stock’s 50 day moving average is $27.92 and its two-hundred day moving average is $26.18. The firm has a market cap of $3.93 billion, a P/E ratio of -12.96 and a beta of 1.02.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Equities research analysts forecast that Zai Lab Limited will post -2.58 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a report on Tuesday. Bank of America reissued a “neutral” rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a report on Monday.

Hedge Funds Weigh In On Zai Lab

Hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Zai Lab in the fourth quarter valued at approximately $29,000. Pictet Asset Management Holding SA purchased a new position in shares of Zai Lab in the fourth quarter valued at approximately $31,000. Barclays PLC lifted its position in shares of Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company’s stock valued at $97,000 after acquiring an additional 2,856 shares in the last quarter. US Bancorp DE lifted its position in shares of Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after acquiring an additional 5,534 shares in the last quarter. Finally, Jasper Ridge Partners L.P. purchased a new position in shares of Zai Lab in the fourth quarter valued at approximately $210,000. Hedge funds and other institutional investors own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.